ClinicalTrials.gg
Not yet recruitingNCT06245070Updated Feb 26, 2024

Speech and Voice Outcomes Following HD-tDCS Over the Left SMA

An interventional study of Active transcranial direct current stimulation and Sham transcranial direct current stimulation in Parkinson Disease, sponsored by Louisiana State University and A&M College. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by Louisiana State University and A&M College · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Pharmaceutical and neurosurgical treatments reliably ameliorate the cardinal motor symptoms in PD but, they often yield inconsistent outcomes for speech and voice disorders, with some studies showing exacerbation of pre-treatment deficits. Therefore, it is crucial to develop and optimize novel approaches that could simultaneously improve speech and voice deficits in PD and facilitate existing behavioral interventions. This project will investigate the immediate and short-term effects of multiple sessions of HD-tDCS over the left SMA on speech and voice deficits in PD.

Read the detailed description

Parkinson's disease (PD) is a movement disorder that affects more than one million individuals in the United States. Over 90 percent of individuals with PD manifest speech and voice impairments in the course of their disease, which can significantly compromise patients' quality of life. While pharmaceutical intervention and deep brain stimulation reliably improve the cardinal motor symptoms of PD, such as tremor, rigidity, and bradykinesia, the effects of these treatments on speech and voice are inconsistent, with some studies showing the exacerbation of pre-treatment deficits. This inconsistency often occurs because treatments are calibrated to ameliorate limb motor symptoms, with no direct optimization to improve speech and voice functions. However, there is no established non-invasive neurostimulation protocol for communication disorders in PD. Increasing evidence supports the application of non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) to improve both motor and non-motor symptoms in PD. However, limited evidence exists regarding the application of tDCS to improve speech and voice disorders in PD. Moreover, there is no established long-term effect of tDCS on speech and voice deficits in PD. In this proposed study, we will address these gaps by investigating the immediate and short-term effects of high definition-transcranial direct current stimulation (HD-tDCS) over the left supplementary motor area (SMA) on speech and voice deficits in 24 PD and 24 matched control participants.

02

Conditions studied

  • Parkinson Disease

Keywords

  • Brain stimulation
  • Supplementary motor area
  • Speech
  • Voice
03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 48 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Louisiana State University and A&M College is the lead sponsor of 13 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Parkinson's disease
  • Native English speakers
  • Adequate age-relative hearing and vision to perform the outlined tasks
  • Able to provide their own written consent

Exclusion criteria

Exclusion Criteria :

  • Neurological disorders besides Parkinson's disease
  • Previous brain surgery including deep brain stimulation
  • Clinical diagnosis of dementia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Active high definition transcranial direct current stimulation (HD-tDCS)

    High-definition anodal transcranial direct current stimulation (2 milliamps \[mA\]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.

    Device: Active transcranial direct current stimulation

  • Experimental
    Sham high definition transcranial direct current stimulation (HD-tDCS)

    High-definition sham transcranial direct current stimulation (2 milliamps \[mA\]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).

    Device: Sham transcranial direct current stimulation

Interventions

  • DeviceActive transcranial direct current stimulation

    HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.

  • DeviceSham transcranial direct current stimulation

    HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.

06

What researchers measure

Primary outcomes

  1. Voice loudness measures

    Acoustics measures of voice loudness including voice intensity (dB), shimmer (Cycle-to-cycle voice intensity perturbation) and smoothed cepstral peak prominence will be calculated for each participant.

    Time frame: Acoustic measures related to voice loudness will be measured at baseline, immediately after the last session of stimulation, one week and one month after the las stimulation session.

  2. Fundamental frequency measures

    Changes in the accuracy rate (percentage of correct repetitions) of non-word repetition

    Time frame: Fundamental frequency (F0), jitter (Cycle-to-cycle voice F0 perturbation) and harmonic to noise ration will be calculated for each participant.

  3. Accuracy of syllable repetition

    The number of syllables that correctly produced during syllable repetition task will be calculated for each participant.

    Time frame: Accuracy rate for syllable repetition will be measured at baseline, immediately after the last session of stimulation, one week and one month after the las stimulation session.

  4. Speech rate

    The speech rate ( number of syllables per second) will be calculated during a syllable repetition task for each participant.

    Time frame: Speech rate will be measured at baseline, immediately after the last session of stimulation, one week and one month after the las stimulation session.

  5. Speech rate stability

    Variability in speech rate across trials for each syllable length ( 1, 2, and 3 ) will be calculated for each participant.

    Time frame: Speech rate stability will be measured at baseline, immediately after the last session of stimulation, one week and one month after the las stimulation session.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Participants' data are confidential. de-identified data will be publicly available after final analysis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Jan 2028, 35 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 35 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 7, 2024
StartEst.
Feb 2, 2025
Primary completionEst.
Jan 2, 2028
CompletionEst.
Jun 2, 2028
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245070
Lead sponsor
Louisiana State University and A&M College
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Feb 2, 2025 (estimated)
Primary completion
Jan 2, 2028 (estimated)
Completion
Jun 2, 2028 (estimated)
Last update
Feb 26, 2024

Study contacts

Karim Johari
Contact
karimjohari@lsu.edu
225-578-3934

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion